文献速递白血病造血干细胞移植与细胞治疗

B细胞急性淋巴细胞白血病儿童、青少年及年轻成人接受替沙基仑赛治疗无应答及复发后的结局

Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
PubMed 文献 · J Clin Oncol · 2022-09-15

这项回顾性多机构研究纳入80例接受替沙基仑赛治疗后无应答(n=23)或复发(n=57)的B细胞急性淋巴细胞白血病儿童及年轻成人,分析生存结局与治疗变量。无应答者12个月总生存率为19%,复发者12个月总生存率为52%;CD19阴性复发者12个月总生存率30%,显著低于CD19阳性复发者的68%(P=0.0068)。

要点

  • 无应答者12个月总生存率仅19%(95%CI 7-50)。
  • 复发者12个月总生存率52%(95%CI 38-71)。
  • CD19阴性复发者12个月总生存率显著低于CD19阳性复发者(30% vs 68%,P=0.0068)。

核心结论

  • 替沙基仑赛无应答患者生存结局差。
  • 替沙基仑赛治疗后复发患者仍可被挽救,但CD19阴性复发与生存结局降低显著相关。

研究设计与样本

  • 回顾性多机构研究,纳入80例接受替沙基仑赛治疗后无应答(n=23)或复发(n=57)的B细胞急性淋巴细胞白血病儿童、青少年及年轻成人。
  • 分析基线特征与结局的关联,并建立生存率及挽救治疗方法。

主要发现

  • 无应答者(n=23)12个月总生存率为19%(95%CI 7-50)。
  • 无应答患者中95%在输注前有高疾病负荷。
  • 156例形态学缓解者中,12个月累积复发发生率为37%(95%CI 30-47),其中CD19阳性复发21%(95%CI 15-29),CD19阴性复发16%(95%CI 11-24),中位随访380天。
  • 57例复发患者中,复发后12个月总生存率为52%(95%CI 38-71)。
  • CD19阴性复发者12个月总生存率为30%(95%CI 14-66),CD19阳性复发者为68%(95%CI 49-92),差异显著(P=0.0068)。

关键数值与推荐

  • 无应答:12个月总生存率19%(95%CI 7-50,n=23)。
  • 复发:12个月总生存率52%(95%CI 38-71,n=57)。
  • CD19阴性复发12个月总生存率30%(95%CI 14-66) vs CD19阳性复发68%(95%CI 49-92),P=0.0068。
  • 156例形态学缓解者12个月累积复发率37%(95%CI 30-47),CD19阳性21%(95%CI 15-29),CD19阴性16%(95%CI 11-24)。

临床怎么用

  • 伊诺妥珠单抗、CAR再输注和化疗是复发后最常用的挽救治疗,但治疗顺序和反应的高度变异性限制了跨挽救方法的疗效分析。

局限性

  • 治疗顺序和反应的高度变异性限制了跨挽救方法的疗效分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nonresponse and relapse after CD19-chimeric antigen receptor (CAR) T-cell therapy continue to challenge survival outcomes. Phase II landmark data from the ELIANA trial demonstrated nonresponse and relapse rates of 14.5% and 28%, respectively, whereas use in the real-world setting showed nonresponse and relapse rates of 15% and 37%. Outcome analyses describing fate after post-CAR nonresponse and relapse remain limited. Here, we aim to establish survival outcomes after nonresponse and both CD19+ and CD19- relapses and explore treatment variables associated with inferior survival. METHODS: We conducted a retrospective multi-institutional study of 80 children and young adults with B-cell acute lymphoblastic leukemia experiencing nonresponse (n = 23) or relapse (n = 57) after tisagenlecleucel. We analyze associations between baseline characteristics and these outcomes and establish survival rates and salvage approaches. RESULTS: The overall survival (OS) at 12 months was 19% across nonresponders (n = 23; 95% CI, 7 to 50). Ninety-five percent of patients with nonresponse had high preinfusion disease burden. Among 156 morphologic responders, the cumulative incidence of relapse was 37% (95% CI, 30 to 47) at 12 months (CD19+; 21% [15 to 29], CD19-; 16% [11 to 24], median follow-up; 380 days). Across 57 patients experiencing relapse, the OS was 52% (95% CI, 38 to 71) at 12 months after time of relapse. Notably, CD19- relapse was associated with significantly decreased OS as compared with patients who relapsed with conserved CD19 expression (CD19- 12-month OS; 30% [14 to 66], CD19+ 12-month OS; 68% [49 to 92], P = .0068). Inotuzumab, CAR reinfusion, and chemotherapy were used as postrelapse salvage therapy with greatest frequency, yet high variability in treatment sequencing and responses limits efficacy analysis across salvage approaches. CONCLUSION: We describe poor survival across patients experiencing nonresponse to tisagenlecleucel. In the post-tisagenlecleucel relapse setting, patients can be salvaged; however, CD19- relapse is distinctly associated with decreased survival outcomes.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Schultz LM, Eaton A, Baggott C, et al. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022. PMID: 36108252. doi:10.1200/JCO.22.01076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。